Method of various suppulative-inflammatory skin and mucous process treatment

FIELD: medicine; pharmacology.

SUBSTANCE: medicinal agent for various suppulative-inflammatory skin and mucous process treatment is characterised by the fact that it has gel consistency and contains metronidazole or biocomplex of metronidazole and zinc, or biocomplex of metronidazole and cobalt, or biocomplex of metronidazole and copper, or biocomplex of metronidazole and manganese, trimecaine, ascorbic acid, spirulyna platensysm, clove essence, or peach essence, or rose essence, water, as well as hydrophilic base - water-soluble devivative of cellulose, or methylcellulose, or carboxymethyl cellulose, or carboxymethyl cellulose sodium salt, taken in specified ratio. Medicinal agent for various suppulative-inflammatory skin and mucous process treatment, is characterised by the fact that it has ointment consistency contains metronidazole or biocomplex of metronidazole and zinc, or biocomplex of metronidazole and cobalt, or biocomplex of metronidazole and copper, or biocomplex of metronidazole and manganese, trimecaine, ascorbic acid, spirulyna platensysm, clove essence, or peach essence, or rose essence, water, as well as hydrophilic base - fusion of polyethylene oxide-400 and polyethylene oxide-1500 taken in specified ratio.

EFFECT: agents described above are effective for various suppulative-inflammatory skin and mucous process treatment.

2 cl, 5 tbl

 

The invention relates to medicine, namely to funds with multifactorial effects on inflammatory processes of the skin and used in surgery, dermatology, gynecology, proctology, ENT.

Known gel cleanser "Metrogyl dent", which as the active substance contains metronidazole and chlorhexidine. Excipients: disodium edetate, menthol, saccharin sodium, propylene glycol, carbomer-940, purified water.

The disadvantages of gel Metrogylum dent" can be attributed to its use only for the treatment and prevention of infectious-inflammatory diseases of the oral cavity.

Known remedy ointment the vegetable "levomekol, FS 42-2922-98 widely used for the local treatment of purulent infection. As active substances ointment the vegetable "levomekol contains chloramphenicol and methyluracil and cooked on hydrophilic polietilenoksidnoy basis. Used for the treatment of wounds infected with a mixed flora, including staphylococci, Pseudomonas aeruginosa and Escherichia coli.

The closest is the gel Metrogylum", approved by the Pharmacological Committee SRF March 1, 2004, street No. 56, reference number: P # 011666/04. As the active substance gel Metrogylum contains metronidazole and excipients: propylhydroxybenzoate, propylene glycol, carbomer-940, edetate Dean is sodium, sodium hydroxide, water.

The disadvantages of gel Metrogylum" can be attributed to only intravaginal application and should not be used in otorhinolaryngology.

The objective of the invention is to increase the possible traumas heal wounds, creating a highly efficient from the point of view of bioavailability of drugs having multiple therapeutic effect on inflammatory processes and improving its regenerating effect.

The invention lies in the fact that the tool consists of metronidazole or bio-complexes with metals: zinc (II), copper(II), cobalt(II), manganese(II), trimekainom, spirulina platensis, ascorbic acid, hydrophilic base, essential oils (clove, peach).

This object is achieved in the following ways:

1. The tool is made in the form of gel contains metronidazole, or ecosystem metronidazole with zinc, or ecosystem metronidazole with cobalt, or ecosystem metronidazole with copper, or ecosystem metronidazole with manganese, trimekain, ascorbic acid, spirulina is platensis, essential oil of clove, or peach, or pink, water, and a hydrophilic base is a water - soluble derivative of cellulose, or methyl cellulose, or carboxymethyl cellulose, or sodium carboxymethyl cellulose, the ri, the following ratio of components in g per 100 g:

Metronidazole or bio-complexes with metals
zinc (II), copper(II), cobalt(II), manganese(II)0,20-0,50
Trimekain2,00-4,00
Ascorbic acid1,00-3,00
Spirulina platensis1,00-2,00
Essential oil0,20-0,40
Hydrophilic base1,00-10,00
Water80,10-94,60

2. The tool is made in the form of ointments and contains metronidazole, or ecosystem metronidazole with zinc, or ecosystem metronidazole with cobalt, or ecosystem metronidazole with copper, or ecosystem metronidazole with manganese, trimekain, ascorbic acid, spirulina is platensis, essential oil of clove, or peach, or pink, water, and hydrophilic base alloy of polyethylene oxide-400 and polyethylene oxide-1500, in the following ratio of components in g per 100 g:

Metronidazole or bio-complexes with metals
zinc (II), copper(II), cobalt(II), manganese(II)0,20-0,50
Trimekain2,00-4,00
Ascorbic acid1,00-3,00
Spirulina platensis1,00-2,00
Essential oil0,20-0,40
Hydrophilic base:1,00-10,00
- polyethylene oxide-40068,08-74,00
- polyethylene oxide-150017,02-18,50
Water3,00-5,00

The invention allows to prolong the action of drugs and, thereby, increase the atraumatic treatment, especially burns and extensive trophic skin lesions.

As a drug gel or ointment contains a substance which is suitable for outdoor and/or indoor use.

Gel or ointment contains medicine in an amount to provide its therapeutic effect.

As a drug gel or ointment contains at least one component selected from the group including antimicrobial drugs, anesthetics, vitamins, substances that promote skin regeneration, or a mixture of these substances.

As an antimicrobial agent in the gel contains, for example, metronidazole or bio-complexes with metal salts.

As vitamin a gel or ointment contains, for example, ascorbic acid.

As a substance acting on the regeneration of cells, gel or ointment contains, for example, spirulina is platensis.

is as an anesthetic gel or ointment contains for example, trimekain.

Trimekain (α-diethylamino-2,4,6-trimethylaniline hydrochloride) - white or white with a faint yellowish tinge crystalline powder, very slightly soluble in water, easily in alcohol; has a high activity in all types of anesthesia, especially surface (FS 42-2390-92 "Trimekain"; Pryanishnikov N.T. Clinical application of trimekainom // Surgery. - 1966. No. 8. - P.51-55; Mashkovsky PPM Medicines. - Kharkov: Torsing, 1997. - T.1. S).

Ascorbic acid (L-Ascorbic acid) is a white crystalline powder sour taste. Easily soluble in water, soluble in alcohol; has strong antioxidant properties, involved in the formation of tetrahydrofolate acid and regeneration of the tissues, the synthesis of steroid hormones, collagen, procollagen (Register of medicines).

Cuts Spirulina platensis (No. R, 07.05.2003) - contains balanced amounts needed for human essential amino acids, vegetable fats, with a predominance of unsaturated fatty acids, vitamins a (in the form of beta carotene),1In2In12E, Inositol, minerals and trace elements, natural biologically active pigments (chlorophyll, phycocyanin, and others); normalizes metabolism, stimulates the immune system, promotes the excretion of current is ins.

Essential oils (clove, peach) - thin, transparent, colorless or yellowish liquid with a characteristic pungent smell. Possess an antibacterial effect, weak anesthetic, as well as the ability to cause local irritation of the skin and local hyperemia, enhance the absorption of drugs. Used as antiseptic and anti-inflammatory drugs (Mashkovsky PPM Medicines. - Kharkov: Torsing, 1997. - T.1, s, 342. Tarasenko VS Essential oils. The content and composition in plants. - Kiev: Nauk. Dumka, 1985. - 264 S.).

As the hydrophilic base offers a water-soluble derivative of cellulose as the most optimal for the preparation of ointments used for the treatment of local inflammatory processes and meet all the requirements of the basics of this type.

As water-soluble cellulose derivatives take the following known substance.

The water-soluble methylcellulose brand MC-100 or MC-400, produced by TU-6-55-221-137-93 (RI "Polymersintez", Vladimir), carboxymethylcellulose, reference Reagents for biochemistry and research in the field of natural Sciences, SIGMA, 1999, s, sodium salt of carboxymethylcellulose.

Sodium-carboxymethylcellulose - sodium salt of simple cellulose ether and glycolic acid White or slightly yellowish powder or fibrous product is odourless, soluble in cold and hot water. Forms highly viscous solutions. Nekantserogenno. Widely used in cosmetic, perfume industry, in medicine and pharmacy as an auxiliary substance in eye drops, emulsions, suspensions, ointments, consisting of toothpastes, tablets, etc. (Registration number 68/333/16; the State register of medicines. M., 2000. - 1203 S.; Polymers in pharmacy. Edited Aiemchawee, Metalasia. - M.: Medicine, 1985. - 256 S.)

Carboxymethylcellulose is a product of the interaction of cellulose with monochloracetic acid; solid white. (Chemistry and technology cellulose derivatives. Ed. Lpparameter and Ulogov, Vladimir, 1968.).

Polyethylene oxides (PEO-400, PEO-1500) - liquid or solid consistency, depending on the degree of polymerization; soluble in water, alcohol, chloroform, benzene; practically insoluble in ether and petroleum ether; do not mix with hydrocarbons and fats, and form with them the emulsion; insensitive to changes in pH; resistant to high temperatures, stable during storage, they have a strong dehydrating effect (Walnut VM Basis for ointments. - M.: Medicine, 1975. - 55; ANCOVA A.I., Alysin M.L. Polymers in pharmacy. - M.: Medicine, 1985. - 256; B. I. Dashevskaya, bodnia V.M., Gluzman - / / pharmacy. - 1990 - No. 6. - C.31-34).

As the basis of features alloy PEO-400 and PEO-1500 in the ratio 8:2, respectively, as the most optimal for the preparation of ointments used for the treatment of local inflammatory processes and meet all the requirements of the basics of this type.

For the proposed composition of the multicomponent gel or ointment with regard to the nature and properties included in their ingredients developed the technology of cooking, which include three stages.

Technology of preparation of the gel: the dissolution of metronidazole (or biocomplex with zinc, or biocomplex with cobalt, or biocomplex with copper, or biocomplex with manganese) in hot distilled water and the introduction of trimekainom, ascorbic acid, spirulina platensis; producing a gel base; mixing a gel base and other components dissolved to obtain a homogeneous mass.

The 1st stage. In hot distilled water (70° (C) dissolving metronidazole (or bio-complex with zinc, or bio-complex with cobalt, or bio-complex with copper, or bio-complex with manganese) under stirring on a magnetic stirrer. In the resulting solution was successively under stirring introduced trimekain, ascorbic acid and spirulina platensis.

The 2nd stage. Prepare a water solution of methyl cellulose, or CABAC is metiltselljulozy, or sodium salt of carboxymethylcellulose.

The 3rd stage. Solution the components of the gel is combined with the solution containing the remaining ingredients, adding it in small portions. Upon cooling gel to room temperature imposed on drops of essential oil (or clove, or peach, or pink).

Technology of preparation of ointments: the dissolution of metronidazole (or biocomplex with zinc, or biocomplex with cobalt, or biocomplex with copper, or biocomplex with manganese) in hot distilled water and the introduction of trimekainom and ascorbic acid; production of ointment bases, and an introduction to the basis of spirulina platensis and other components to obtain a homogeneous mass.

The 1st stage. In hot distilled water (70° (C) dissolving metronidazole (or bio-complex with zinc, or bio-complex with cobalt, or bio-complex with copper, or bio-complex with manganese) under stirring on a magnetic stirrer. In the resulting solution was successively under stirring introduced trimekain and ascorbic acid.

The 2nd stage. Alloy components ointment bases (PEO-400 and PEO-1500).

The 3rd stage. In the liquid alloy oxides added in small portions under stirring spirulina platensis and the solution containing the other ingredients. Upon cooling ointments to room temperature imposed on the apply essential oil.

An example method for producing a gel.

In 30 ml of distilled water is dissolved 0.2 g of metronidazole (or bio-complex with zinc, or bio-complex with cobalt, or bio-complex with copper, or bio-complex with manganese) with stirring in hot water and the resulting solution was sequentially injected 2.0 g of trimekainom, 1.0 g of ascorbic acid and 1.0 g of spirulina platensis. In 64,6 ml of distilled water dissolve 1 g of methylcellulose or carboxymethylcellulose, or sodium salt of carboxymethylcellulose.

In the resulting mass is introduced with stirring, a solution containing an antimicrobial drug (metronidazole, or bio-complex with zinc, or bio-complex with cobalt, or bio-complex with copper, or bio-complex with manganese), trimekain, ascorbic acid and spirulina platensis. Then the resulting mass is added 0.2 g of clove or peach oil and everything is thoroughly mixed.

In appearance the prepared gel is a homogeneous greenish mass of gel-like consistency, slightly bitter taste that causes numbness in the tip of the tongue with a pleasant smell of essential oils.

An example method for producing ointments.

In 5 ml of distilled water is dissolved 0.2 g of metronidazole (or bio-complex with zinc, or bio-complex with cobalt, or bio-complex with copper, or the ecosystem, with Mar is the like) under stirring in hot water and the resulting solution was sequentially injected 2.0 g of trimekainom, 1.0 g of ascorbic acid.

In a water bath alloys 74,00 g PEO-400 and 18.5 g of PEO-1500. In the resulting molten alloy is injected in small portions with stirring spirulina platensis and the solution containing the other ingredients. Mix thoroughly and after cooling, enter 0.2 g of essential oil (or clove, or peach, or pink).

In appearance the prepared ointment is a homogeneous mass of gel-like consistency greenish color, bitter taste, causing numbness in the tip of the tongue, having a fragrant smell of essential oils.

Study the specific activity of the proposed formulations of gels and ointments (table 1, 2) was performed in experiments in vitro and in vivo.

Table 1
Composite compounds gels
№ p/pComponent nameNo. ointment composition
12345
1.Antimicrobial drugs:
Metronidazole0,2 /td>
Biocomplex metronidazole with zinc0,2
Biocomplex metronidazole with cobalt0,2
Biocomplex metronidazole with copper0,2
Biocomplex metronidazole with manganese0,2
2.Trimekain2,02,02,02,02,0
3.Ascorbic acid1,01,01,01,01,0
4.Spirulina platensis1,01,01,01,01,0
5.Clove oil0,20,20,20,20,2
6.Sodium salt carboxymethylcelluose (or methylcellulose or carboxymethylcellulose)1,0 1,01,01,01,0
7.Water94,694,694,694,694,6

td align="left">  
Table 2
Composite compounds ointments
№ p/pComponent nameNo. ointment composition
12345
1.Antimicrobial drugs:
Metronidazole0,2
Biocomplex metronidazole with zinc0,2
Biocomplex metronidazole with cobalt0,2
Biocomplex metronidazole with copper0,2
Biocomplex metronidazole with manganese0,2
2.Trimekain2,02,02,02,02,0
3.Ascorbic acid1,01,01,01,01,0
4.Spirulina platensis1,01,01,01,01,0
5.Clove oil0,20,20,20,20,2
6.PEO-40074,074,074,074,074,0
7.PEO-150018,518,518,518,518,5
8.Water3,03,03,03,03,0

Study of antimicrobial activity of the preparations was performed by the method of diffusion in agar on solid nutrient media by analyzing the zones of inhibition of growth of test organisms used for the determination of antimicrobial action of medicines. ISS is adowanie carried out in respect of the following standard strains of microorganisms: Staphylococcus aureus ATCC 6538-P, Escherichia coli ATCC 25922, Bacillus subtillis ATCC 6633, Candida albicans ATCC 865-653, Pseudomonas aeruginosa ATCC 9027. It is established that an antimicrobial effect is evident in the first three test crops.

The results obtained allowed to set the amplification of antimicrobial action due to the joint presence of metronidazole (or biocomplex metronidazole with zinc, or biocomplex metronidazole with cobalt, or biocomplex metronidazole with copper, or biocomplex metronidazole with manganese), trimekainom, ascorbic acid, spirulina platensis, essential oils and bases water-soluble derivative of cellulose (methylcellulose, carboxymethylcellulose, sodium salt of carboxymethyl cellulose) or PEO-foundations (tables 3, 4).

Table 3
The results of the study of antimicrobial activity gels
№ p/pThe research objectsZones of growth inhibition, mm
Staphylococcus aureus ATCC 6538-PEscherichia coli ATCC 25922Bacillus subtillis ATCC 6633
1.Gel Metrogylum"18,3±0,216,4±0,220,4±0,4
2.Composition No. 123,1±0,428,7± 0,330,2±0,3
3.Composition No. 231,0±0,234,0±0,239,0±0,4
4.Composition No. 330,3±0,133,3±0,237,3±0,3
5.Composition No. 430,9±0,233,5±0,327,9±0,2
6.Composition No. 526,5±0,329,9±0,233,4±0,2
Table 4
The results of the study of antimicrobial activity ointment
№ p/pThe research objectsZones of growth inhibition, mm
Staphylococcus aureus ATCC 6538-PEscherichia coli ATCC 25922Bacillus subtillis ATCC 6633
1.Official ointment the vegetable "levomekol25,2±0,422,3±0,226,9±0,3
2.Composition No. 130,5±0,230,9±0,331,3±0,4
3.Composition No. 235,2±0,337,8±0,440,9±0,3
4.Composition No. 334,3±0,236,2±0,240,1±0,2
5.Composition No. 435,4±0,336,8±0,230,8±0,3
6.Composition No. 530,2±0,231,4±0,332,4±0,2

Local anesthetic activity developed ointments studied in experiments in vivo method Rainier-Jack, based on the change in the sensitivity of the cornea of the rabbit when applied to the sample, expressed in response to a stimulus in the form of a clamping century.

In into the conjunctival eye bag rabbit was introduced with a syringe 0.1 g of the investigated materials. Using a calibrated hairs on the cornea caused rhythmic stimulation with a frequency of 100 beats per minute through 1, 2, 5, 8, 10, 12, 15 min and then every 5 min prior to the closing of the eyelids.

The speed of onset of local anesthesia took time between introduction of the sample ointments and early manifestations of pharmacological action.

The relative strength of anesthetic action is expected, according to the index Rainier, summing the number irritation at 13 dimensions, starting with the 8th min, in the course of an hour.

Indicator full anesthesia believed no blink reflex for 1 min at 100 contacts calibrated hairs with the cornea of the eye.

The duration of General anesthesia by characterizability since the beginning of anesthesia until the full restoration of sensitivity.

The obtained results were processed by the method of variation statistics (GF XI, M, 1987, vol. 1, s), are presented in table 5.

Table 5
Local anesthetic activity by the method of Rainier
The research objectsIndicators anesthesia
The time of onset of anesthesia, minThe duration of anesthesia, minIndex Rainier, usled
3% solution of trimekainom (control)1,0±0,08,5±1,5424,4±9,4
3% gel trimekainom 5% gel Na-CMC1,0±0,060,4±3,11000,4±3,9
3% gel metronidazole (0.5%) 5% gel Na-CMC1,0±0,088,15±2,21300,4±5,6
3% gel biocomplex metronidazole with zinc (0.5%) 5% gel Na-CMC1,0±0,0100,0±1,91300,2±4,3
3% gel biocomplex metronidazole with cobalt (0.5%) 5% gel Na-CMC1,0±0,0100,2±1,81300,0±0,0
3% gel biocomplex metronidazole with copper (0.5%) 5% gel Na-CMC1,0±0,099,8±2,0 1300,0±0,0
3% gel biocomplex metronidazole with manganese (0.5%) 5% gel Na-CMC1,0±0,099,5±1,81300,0±0,0
3% ointment trimekainom on PEO-based1,0±0,070,5±3,11042,5±4,1
3% ointment metronidazole (0.5%) PEO-based1,0±0,095,4±3,21300,0±0,0
3% ointment biocomplex metronidazole with zinc (0.5%) PEO-based1,0±0,0110,2±3,41300,0±0,0
3% ointment biocomplex metronidazole with cobalt (0.5%) PEO-based1,0±0,0109,4±2,11300,0±0,0
3% ointment biocomplex metronidazole with copper (0.5%) PEO-based1,0±0,0to 105.3±1,81300,0±0,0
3% ointment biocomplex metronidazole with manganese (0.5%) PEO-based1,0±0,0102,2±2,01300,0±0,0

High index values Rainier, duration of General anesthesia for the proposed multi-component compositions of gels and ointments (compared with control) indicate not only synergistic action of trimekainom and metronidazole (or biocomplex metronidazole with zinc, or biosample the CA metronidazole with cobalt, or biocomplex metronidazole with copper, or biocomplex metronidazole with manganese), but also about the prolongation of anesthetic effect.

The study ranozazivluchee activity of multicomponent ointment conducted on the model panolayou purulent wounds in vivo. In the experience used adult rats male Wistar rats, weighing 160-180 g Animals were divided into groups: control (untreated), comparison (treatment official 0,2% ointment levomekol) and experimental (treatment developed by the tool).

The total percentage reduction of area of the wound in the dynamics in the experimental group to the 14th day of the experiment was 90,66%in the comparison group - 62,46% and in the control group 45,37%.

According to the dynamics of changes in the area of RAS, clinical, microbiological and histological indicators installed a pronounced therapeutic effect developed tools compared to the official ointment levomekol.

Thus, the proposed drug in comparison with the prototype has higher antimicrobial activity, a strong local anesthetic action and effective wound healing property, which is due to a combination of antimicrobial drug, a local anesthetic, ascorbic acid, spirulina platensis, essential oils and bases that contain odorant orive derived cellulose, and potentiating the action of each other. Developed an optimal method of preparation of the proposed compounds ointments that yields the maximum therapeutic efficacy.

The proposed formulations combined gels and ointments help to expand the range of available drugs used for local treatment of purulent-inflammatory processes of the skin and mucous membranes of various etiologies.

The invention provides multiple therapeutic effect on inflammatory processes, the drug is highly effective from the standpoint of biological availability.

The invention provides a reduction of treatment time by reducing the time required to restore the integrity of the skin.

1. For the treatment of purulent-inflammatory processes of the skin and mucous membranes of various etiologies, characterized by the fact that it is made in the form of gel contains metronidazole, or ecosystem metronidazole with zinc, or ecosystem metronidazole with cobalt, or ecosystem metronidazole with copper, or ecosystem metronidazole with manganese, trimekain, ascorbic acid, spirulina is platensis, essential oil of clove, or peach, or pink, water, and hydrophilic, water-soluble derivative of cellulose and methylcellulose, or carboxymethyl cellulose, or sodium carboxymethyl cellulose in the following ratio of components in g per 100 g:

Metronidazole or bio-complexes with metals0,20-0,50
zinc (II), copper(II), cobalt(II), manganese(II)
Trimekain2,00-4,00
Ascorbic acid1,00-3,00
Spirulina platensis1,00-2,00
Essential oil0,20-0,40
Hydrophilic base1,00-10,00
Water80,10-94,60

2. For the treatment of purulent-inflammatory processes of the skin and mucous membranes of various etiologies, characterized by the fact that it is made in the form of ointments and contains metronidazole, or ecosystem metronidazole with zinc, or ecosystem metronidazole with cobalt, or ecosystem metronidazole with copper, or ecosystem metronidazole with manganese, trimekain, ascorbic acid, spirulina is platensis, essential oil of clove, or peach, or pink, water, and a hydrophilic base: alloy of polyethylene oxide-400 and polyethylene oxide-1500 in the following ratio of components in g per 100 g:

Metronidazole or bio-complexes with metals0,20-0,50
zinc (II), copper(II), cobalt(II), manganese(II)
Trimekain2,00-4,00
Ascorbic acid1,00-3,00
Spirulina platensis1,00-2,00
Essential oil0,20-0,40
hydrophilic base:
the polyethylene oxide-40068,08-74,00
the polyethylene oxide-150017,02-18,50
Water3,00-5,00



 

Same patents:

FIELD: medicine; pharmaceutics.

SUBSTANCE: pharmaceutical formulations contains as reactants 1) betamethasone dipropionate or 2) betamethasone dipropionate combined with gentamicin sulphate or 3) betamethasone dipropionate combined with gentamicin sulphate and clotrimazole. Pharmaceutical formulations contain ointment hydrophobic base containing white petrolatum and target additives - preserving agent and hydrophobic nonaqueous solvent. New pharmaceutical formulations have high antibacterial preserving action, high microbiological purity value and potentised antibacterial specific action showed by produced therapeutic effect and simultaneous prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

EFFECT: prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

18 cl, 11 tbl, 6 ex

FIELD: medicine; pharmaceutics.

SUBSTANCE: this invention refers to medicine agents, specifically to pharmaceutical formulations of analgesic action with prolonged release of reactant containing 3-(3-dimethylamine-1-ethyl-2-methylpropyl)phenol or one of its pharmaceutically acceptable salt in matrix, as well as to tablets for taking twice a day containing specified formulation.

EFFECT: ensured prolonged release of reactant of medicine agents.

13 cl, 1 dwg, 11 ex

FIELD: medicine; pharmacology.

SUBSTANCE: invention is related to the compounds of general formula (I) and their pharmaceutically acceptable salts with properties β2-adrenoreceptor agonists, to the method of their production and based on them pharmaceutical composition. The compounds can be used for treatment of conditions when the symptomatic severity can be reduced by β2- adrenoreceptor activation, e.g., obstructive or inflammatory respiratory diseases. In the general formula (I) , X means -R1-Ar-R2 or -Ra-Y; Ar means phenylen, optionally substituted by group of the row: halogen, hydroxy, C1-C10alkyl, C1-C10alcoxy, phenyl, C1-C10 alcoxy, substituted by phenyl group or phenyl, substituted by C1-C10 alcoxy group; R1 and R2 are bound to the adjacent carbon atoms within Ar group, and either R1 means C1-C10alkylen, and R2 means hydrogen, C1-C10alkyl or halogen, Ra means the bond or C1-C10 alkylen optionally substituted by group of the row: hydroxy, C1-C10 alcoxy, C6-C10aryl or C7-C14aralkyl; Y means C1-C10alkyl, or C2-C10alkynil, optionally substituted by hydroxyl group, C3-C10cycloalkyl, optionally condensed with one or more benzene rings and optionally substituted by group of the row: C1-C10alkyl, C1-C10alcoxy, C3-C10cycloalkyl, C7-C14aralkyl, C7-C14aralkyloxy or C6-C10aryl, where groups C7-C14aralkyl, C7-C14aralkyloxy or C6-C10 aryl are optionally substituted by group of the row: halogen, C1-C10alkyl, C1-C10alcoxy; C6-C10aryl, optionally substituted by group of the row: halogen, hydroxy, C1-C10alkyl, C1-C10alcoxy, C1-C10halogenalkyl, phenoxy, C1-C10alkylthio, C6-C10aryl, 5-6-term saturated heterocyclic ring, containing one nitrogen atom in cycle; phenoxy, optionally substituted by C1-C10alcoxy group; 5-6-term heterocyclic ring, containing one or two nitrogen or oxygen atoms in cycle, and the described heterocyclic ring is optionally substituted by group of the row: C1-C10alkyl, C6-C10aryl, C7-C14aralkyl, C1-C10alcoxycarbonil or 5-7-term heterocyclil (C1-C10)alkyl, containing one nitrogen atom in cycle; -NRdRe, where Rd means hydrogen or C1-C10alkyl, and Re means C1-C10alkyl, or Re means C6-C10aryl, or Re means 5-6-term heterocyclic ring, containing one nitrogen or sulfur atom in cycle, and the ring is optionally substituted by halogen-substituted phenyl group or Re means C6-C10arylsypfonil, optionally substituted by groups C1-C10alkylamino or di(C1-C10alkyl)amino; -SRf, where Rf means C6-C10aryl or C7-C14aralkyl, optionally substituted by group of row: halogen or C1-C10halogenalkyl; or -CONHRg, where Rg means C6-C10aryl, provided, if Ra means the bond, then Y doesn't mean C1-C5alkyl.

EFFECT: compound can prevent or reduce symptom's intensity.

15 cl, 4 tbl, 157 ex

FIELD: chemistry.

SUBSTANCE: invention covers new compounds of formula I or its salts suitable for pharmacology: , where R1 is selected from phenyl, pyridyl, thienyl, difurylglyoxal, imidazolyl, pyrrolyl and thiazolyl; R2, R3 and R4 independently are d-zalkyl or halogenated C1-zalkyl; and R5 is hydrogen. And also new intermediate compounds formula III: , where R2, R3 and R4 independently are C1-3alkyl or halogenated C1-6alkyl; and R5 is hydrogen. Invention also covers method of production of compound formula I and their applications.

EFFECT: production of new biologically active compounds.

12 cl, 9 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: the present deals with compositions, kits and their usage for manufacturing medicinal preparations for treating immuno-inflammatory disorders out of the group consisting of rheumatoid arthritis, psoriasis, ulcerous colitis, Crohn's disease, ankylosing spondylitis, multiple sclerosis (MS), type I diabetes, systemic lupus erythematosus, Sjogren's syndrome, fibromyalgia and insult-induced lethality of cerebral cells and, also, for suppressing the production of one or more pro-inflammatory cytokines. The compositions suggested contain the combination of two active ingredients: (i) dipyridamol and (ii) corticosteroid. Such a combination provides the suppression of immune inflammation due to decreasing pro-inflammatory cytokines, such as TNFα by hundreds times.

EFFECT: higher efficiency.

54 cl, 4 ex, 3 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to drugs and concerns non-narcotic synthetic analgesic agent. Agent comprises derivative of gamma-pyrone as an active component chosen from group consisting of meconic acid, methyl-comenic acid, comenic acid taken in the amount from 0.05 mg to 300 mg for a single dose, and a pharmacologically compatible liquid filling agent in the following ratio of components, wt.-%: active substance, 0.5-95, and liquid filling agent, the balance. Agent represents a formulation designated for systemic dosing. Also, invention discloses a method for treatment of pain syndrome of different etiology based on administration of non-narcotic synthetic analgesic agent. Invention provides the novel synthetic non-narcotic analgesic agent without negative adverse effects.

EFFECT: valuable medicinal properties of agent.

9 cl, 2 tbl, 7 ex

FIELD: genetic engineering, medicine.

SUBSTANCE: invention proposes chimeric protein (ANTH1) consisting of a sequence corresponding to 60 amino acids of N-terminal region of interleukin-2 and extracellular moiety of N-terminal moiety of human gamma-interferon alpha-chain that are bound each with other by peptide Ala-His-Met-Met. Protein ANTH1 possesses capacity to inhibit biological activity of gamma-interferon and/or interleukin-2 and therefore it can be used in preparing drugs designated for treatment of diseases mediated by activity of interleukin-2, gamma-interferon or both these cytokines, in particular, in treatment of cerebrospinal sclerosis, erythematosus lupus, proliferative arthritis, diabetes mellitus and others. Invention can be used in medical-biological industry.

EFFECT: valuable medicinal and biological properties of protein.

13 cl, 1 tbl, 10 dwg, 11 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to novel 2-azaspiro[4.6]undecan-3-thiones of the formula (I): wherein X1 and X2 represent in common =S; R1 means hydrogen atom (H); R2 means H; R3 means H, -RQ2; Z means 5-8-membered monocyclic saturated ring bound through a general C-atom with the first azaheterocyclic ring; R8 means (C1-C5)-alkylcarbonyl; Q2 means H, or its pharmaceutically acceptable salts used as an analgesic agent. This allows their using in treatment of chronic inflammatory and/or neuropathic pain.

EFFECT: valuable medicinal properties of compounds.

17 cl, 1 tbl, 1 dwg, 8 ex

FIELD: organic chemistry, chemical technology, pharmacy.

SUBSTANCE: invention relates to a novel method for synthesis of NO-donor compounds of the formula (IV): MLT1AT2-COO-X-ONOn (IV). Method involves carrying out the following steps: (1) reaction of compound of the formula (I): MLT1AT2-COOH (I) with compound of the formula: HO-X-OH using acid or dehydrogenating agent and the first solvent followed by optional purification by extraction or crystallization in order to obtain compound of the formula: MLT1AT2-COO-X-OH (II); (2) reaction of compound of the formula (II) with compound of the formula: RSO2Cl using the second solvent, base and, optionally, catalyst followed by purification by extraction and crystallization in order to obtain compound of the formula (III): MLT1AT2-COO-X-OSO2R (III); (3) reaction of compound of the formula (III) with compound of the formula: Y-NO3 using the third solvent and, optionally, catalyst followed by optional crystallization for preparing compound of the formula (IV): MLT1AT2-COO-X-ONOn (IV) wherein group MLT1AT2 is chosen from group consisting of the following substances:

and wherein X is chosen from group consisting of linear -(CH2)w1- wherein w1 = 2-10; -(CH2-CH2O)2-CH2-CH2- and -CH2-C6H4-CH2-; R is chosen from group consisting of (C1-C8)-alkyl, phenyl, phenylmethyl, (C1-C4)-alkylphenyl, halogenphenyl, nitrophenyl, acetylaminophenyl, halogen atom, -CF3 and n-C4F9; Y-NO3 represents lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate and tetraalkyl ammonium nitrate wherein alkyl represents (C1-C18)-alkyl that can be linear or branched, and their mixture; m = 2, and under condition that when MLT1AT2-COOH represents naproxen then X doesn't mean -(CH2)4. Also, invention relates to using a method for synthesis of compounds of formulas (IVa), (IVb), (IVc) and (IVd) given in the invention description, their novel intermediate compounds of formulas (IIIa), (IIIb), (IIIc) and (IIId) given in the invention description, crystalline form of 2-[2-(nitrooxy)ethoxy]ethyl{2-[(2,6-dichlorophenyl)amino]phenyl}acetate and to a method for its synthesis, and its using for preparing a drug used in pain and/or inflammation treatment, using compounds of the formula (III) as intermediate compounds. Also, invention relates to using intermediate compounds of formulas (IIIa), (IIIb), (IIIc) and (IIId) used for synthesis of compounds of formulas (IVa), (IVb), (IVc) and (IVd). Invention provides a novel method for synthesis of compounds of the formula (IV).

EFFECT: improved method of synthesis.

32 cl, 2 tbl, 5 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition and a method for treatment of rhinitis and catarrhal symptoms. The composition comprises the effective dose of the following drug: (a) ibuprofen; (b) pseudoephedrine, and (c) chlorpheniramine wherein the effective amount of pseudoephedrine or chlorpheniramine or both is 75% or less of their standard doses, and the amount of ibuprofen is the standard dose. Also, invention relates to a pharmaceutical composition that comprises the effective dose of each component: (a) ibuprofen; (b) pseudoephedrine; (c) chlorpheniramine, and (d) dextromethorphan wherein the effective amount of pseudoephedrine or chlorpheniramine maleate or dextromethorphan is 75% or less of their standard doses, and the amount of ibuprofen is the standard dose.

EFFECT: valuable medicinal properties of compositions, improved method of treatment.

22 cl, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: nidus is sanitised with air-plasma flow containing nitrogen oxide from distance 20-25 cm. Each area of nidus sized 1cm x 1cm is exposed for 8-9 seconds. Total exposure time corresponds to wound area. Then wound surface as covered with gel as medicinal agent during I and II phase of wound process. Gel contains myelopid concentrated 3000 mcg/ml - 66 ml, aerosyl - 7.5 g, glycerin - 26.5 g. Gel covers total wound surface.

EFFECT: method enables to reduce inflammatory process course and increase regenerative processes due to myelopid application.

2 ex, 2 cl

FIELD: medicine; traumatology.

SUBSTANCE: for this purpose wound area is locally oxygenated by means of subcutaneous paravulnar injection of oxygenic perfluoran. Perfluoran is dosed 0.1-0.5 ml per 1 kg of body weight, daily until oedema comes off. Besides 5 minutes before perfluoran introduction lidasa dosed 16-32 units is subcutaneous introduced. And 10 minutes after perfluoran introduction contrast bathes are taken during 10-15 minutes.

EFFECT: prevents reperfusion and purulo-necrotic complications, anaerobic infection; lympho-drainage; improves oxygen supply to ischemic tissues; reduces treatment and rehabilitation expenses.

2 cl, 1 ex

FIELD: cosmetics.

SUBSTANCE: invention refers to balneological agents based on reindeers', maral's and Manchurian deer's antlers, and can be used in medicine and cosmetics for prevention and treatment of human coetaneous covering and viscera. Liquid concentrate of antlers contains non-ethanolic extract of superdispersed antler powder, glycerine and propylene glycol as dissolvent. Total cosmetic activity of liquid antler concentrate is not less than 5000 mOcm/l. Liquid concentrate composition includes as follows, mass %: superdispersed antler powder 5.0-28.0; glycerine and/or propylene glycol 38.0-70.0; water - rest up to 100%. Concentrate can additionally contain dimexyde in amount 20.0-50.0 mass % of its formulation and/or nonionic surfactant polysorbate 80 in amount 5.0-10.0 mass % of its formulation.

EFFECT: easy to use consistency; is agent of long-term storage, end product does not contain toxic preserving agents.

3 cl, 9 ex, 1 tbl

FIELD: medicine; pharmaceutics.

SUBSTANCE: pharmaceutical formulations contains as reactants 1) betamethasone dipropionate or 2) betamethasone dipropionate combined with gentamicin sulphate or 3) betamethasone dipropionate combined with gentamicin sulphate and clotrimazole. Pharmaceutical formulations contain ointment hydrophobic base containing white petrolatum and target additives - preserving agent and hydrophobic nonaqueous solvent. New pharmaceutical formulations have high antibacterial preserving action, high microbiological purity value and potentised antibacterial specific action showed by produced therapeutic effect and simultaneous prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

EFFECT: prevention of by-effect local complication caused by activation of bacterial and mycotic infections.

18 cl, 11 tbl, 6 ex

FIELD: medicine; surgery.

SUBSTANCE: suppurative focus is primary surgically treated with radio-wave surgery system "Dento-Surg". Incision is made with needle electrode at power 45-65 W. Necrotic suppurative core is removed with loop electrode at power 45-65 W. Wound is rinsed with perftoran emulsion. Perftoran emulsion bandage is applied, and wound is impacted with alternative magnetic field of frequency 50 Hz, magnetic induction 30 mTl. Impact time is 8-10 minutes. Sessions are carried out daily, 3-5 procedures per course.

EFFECT: decrease of treatment period for patients suffering from abscessing face furuncles.

3 ex

FIELD: medicine; pharmacology.

SUBSTANCE: ointment for burns, dermatoses treatment and wound healing contains turpentine, beeswax, sea-buckthorn oil, cow's butter, pig's fat and biologically active substance selected from: aloe extract, plantain extract, beggars-ticks extract, rosehip extract, St. John's wort oil, linseed oil, calendula oil, bur oil, camomile oil, or propolis.

EFFECT: stimulating effect on regenerative processes in connective tissues and epithelium.

19 ex

FIELD: medicine.

SUBSTANCE: bioactive complex with anti-tumor, antidepressant and wound-healing activities is invented; it contains the secretion of renal tubules of spawning male of thornback - 640-690 mg of solid, and secretion of gills of Atlantic salmon of activated by symbiotic larvae of pearl oyster life cycle - 320-480 mg of solid per 1000 mL of finished product, and five-year-old brandy - the rest. The invented method for treatment of oncology diseases consists in oral administration of the bioactive complex 10-30 mL on an empty stomach 10-40 min before meal not less than twice a day for 2-8 weeks. The invented method for treatment of depressive disorders consists in oral administration of bioactive complex 10-30 mL on an empty stomach 10-40 min before meal not less than twice a day for 2-8 weeks.

EFFECT: invention provides multipurpose ichthyocomplex with powerful anti-inflammatory and antitumor activity and minimal side effects.

6 cl, 6 ex

Compound // 2323940

FIELD: chemistry.

SUBSTANCE: photosensitising agents obtained by reducing a double bond in porphyrinic macrocycle of sulphonated mesotetraphenylporphyrine, preferably disulphonated mesotetraphenylporphyrine, such as TPPS2a. Resulting sulphonated mesotetraphenylchlorines are compounds of formula (I) , (where X stands for -SO3Н; each of n, p, q and r independently stands for 0 or 1; and sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, in particular, 2 or 4), isomers or isomeric mixture. Compounds in accordance with the said invention and pharmaceutically suitable salts thereof have a high extinction coefficient in the region of 630 to 680 nm.

EFFECT: compounds are widely used as photosensitising agents for photochemical internalisation of molecules and photodynamic therapy.

25 cl, 8 ex, 8 dwg

Compound // 2323940

FIELD: chemistry.

SUBSTANCE: photosensitising agents obtained by reducing a double bond in porphyrinic macrocycle of sulphonated mesotetraphenylporphyrine, preferably disulphonated mesotetraphenylporphyrine, such as TPPS2a. Resulting sulphonated mesotetraphenylchlorines are compounds of formula (I) , (where X stands for -SO3Н; each of n, p, q and r independently stands for 0 or 1; and sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, in particular, 2 or 4), isomers or isomeric mixture. Compounds in accordance with the said invention and pharmaceutically suitable salts thereof have a high extinction coefficient in the region of 630 to 680 nm.

EFFECT: compounds are widely used as photosensitising agents for photochemical internalisation of molecules and photodynamic therapy.

25 cl, 8 ex, 8 dwg

Compound // 2323940

FIELD: chemistry.

SUBSTANCE: photosensitising agents obtained by reducing a double bond in porphyrinic macrocycle of sulphonated mesotetraphenylporphyrine, preferably disulphonated mesotetraphenylporphyrine, such as TPPS2a. Resulting sulphonated mesotetraphenylchlorines are compounds of formula (I) , (where X stands for -SO3Н; each of n, p, q and r independently stands for 0 or 1; and sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, in particular, 2 or 4), isomers or isomeric mixture. Compounds in accordance with the said invention and pharmaceutically suitable salts thereof have a high extinction coefficient in the region of 630 to 680 nm.

EFFECT: compounds are widely used as photosensitising agents for photochemical internalisation of molecules and photodynamic therapy.

25 cl, 8 ex, 8 dwg

FIELD: medicine; stomatology.

SUBSTANCE: general and local pharmacotherapy is carried out. Additionally one day after surgery perphtoran dosed to 0.1 ml/kg body weight is singly injected in submucosa of operational interjacent fold.

EFFECT: enables to improve treatment efficiency.

1 ex

Up!